Skip to main content
Top
Published in: Journal of General Internal Medicine 6/2008

01-06-2008 | Clinical Review

Herbal Medicine in the United States: Review of Efficacy, Safety, and Regulation

Grand Rounds at University of California, San Francisco Medical Center

Author: Stephen Bent

Published in: Journal of General Internal Medicine | Issue 6/2008

Login to get access

Abstract

Introduction

Herbal products have gained increasing popularity in the last decade, and are now used by approximately 20% of the population. Herbal products are complex mixtures of organic chemicals that may come from any raw or processed part of a plant, including leaves, stems, flowers, roots, and seeds. Under the current law, herbs are defined as dietary supplements, and manufacturers can therefore produce, sell, and market herbs without first demonstrating safety and efficacy, as is required for pharmaceutical drugs. Although herbs are often perceived as “natural” and therefore safe, many different side effects have been reported owing to active ingredients, contaminants, or interactions with drugs.

Results

Unfortunately, there is limited scientific evidence to establish the safety and efficacy of most herbal products. Of the top 10 herbs, 5 (ginkgo, garlic, St. John’s wort, soy, and kava) have scientific evidence suggesting efficacy, but concerns over safety and a consideration of other medical therapies may temper the decision to use these products.

Conclusions

Herbal products are not likely to become an important alternative to standard medical therapies unless there are changes to the regulation, standardization, and funding for research of these products.
Literature
1.
go back to reference Barnes PM , Powell-Griner E , McFann K , Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data. 2004;343:1–19.PubMed Barnes PM , Powell-Griner E , McFann K , Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data. 2004;343:1–19.PubMed
2.
go back to reference Swerdlow JL. Modern Science Embraces Medicinal Plants. Nature’s Medicine: Plants that Heal. Washington, DC: National Geographic Society; 2000:110–57. Swerdlow JL. Modern Science Embraces Medicinal Plants. Nature’s Medicine: Plants that Heal. Washington, DC: National Geographic Society; 2000:110–57.
3.
go back to reference Swerdlow JL. Medicine Changes: late 19th to early 20th century. Nature’s Medicine: Plants that Heal. Washington, D.C.: National Geographic Society; 2000:158–91. Swerdlow JL. Medicine Changes: late 19th to early 20th century. Nature’s Medicine: Plants that Heal. Washington, D.C.: National Geographic Society; 2000:158–91.
4.
go back to reference Barrett B , Kiefer D , Rabago D. Assessing the risks and benefits of herbal medicine: an overview of scientific evidence. Altern Ther Health Med. 1999;5:40–9.PubMed Barrett B , Kiefer D , Rabago D. Assessing the risks and benefits of herbal medicine: an overview of scientific evidence. Altern Ther Health Med. 1999;5:40–9.PubMed
5.
go back to reference Rotblatt M , Ziment I. Evidence-based herbal medicine. Philadelphia, PA: Hanley & Belfus; 2002. Rotblatt M , Ziment I. Evidence-based herbal medicine. Philadelphia, PA: Hanley & Belfus; 2002.
6.
go back to reference Dubber MJ , Kanfer I. High-performance liquid chromatographic determination of selected flavonols in Ginkgo biloba solid oral dosage forms. J Pharm Pharm Sci. 2004;7:303–9.PubMed Dubber MJ , Kanfer I. High-performance liquid chromatographic determination of selected flavonols in Ginkgo biloba solid oral dosage forms. J Pharm Pharm Sci. 2004;7:303–9.PubMed
7.
go back to reference Institute of Medicine, National Academies Press. Dietary Supplements: A Framework for Evaluating Safety. Washington, DC: National Academies Press; 2005. Institute of Medicine, National Academies Press. Dietary Supplements: A Framework for Evaluating Safety. Washington, DC: National Academies Press; 2005.
8.
go back to reference Harkey MR , Henderson GL , Gershwin ME , Stern JS , Hackman RM. Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr. 2001;73:1101–6. Jun.PubMed Harkey MR , Henderson GL , Gershwin ME , Stern JS , Hackman RM. Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr. 2001;73:1101–6. Jun.PubMed
9.
go back to reference Linde K, Barrett B, Wolkart K, Bauer R, Melchart D. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev. 2006(1):CD000530. Linde K, Barrett B, Wolkart K, Bauer R, Melchart D. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev. 2006(1):CD000530.
10.
go back to reference Turner RB , Bauer R , Woelkart K , Hulsey TC , Gangemi JD. An evaluation of Echinacea angustifolia in experimental rhinovirus infections. N Engl J Med. 2005;353:341–8.PubMedCrossRef Turner RB , Bauer R , Woelkart K , Hulsey TC , Gangemi JD. An evaluation of Echinacea angustifolia in experimental rhinovirus infections. N Engl J Med. 2005;353:341–8.PubMedCrossRef
11.
go back to reference Blumenthal M , Farnsworth NR. Echinacea angustifolia in rhinovirus infections. N Engl J Med. 2005;353:1971–2.PubMedCrossRef Blumenthal M , Farnsworth NR. Echinacea angustifolia in rhinovirus infections. N Engl J Med. 2005;353:1971–2.PubMedCrossRef
12.
go back to reference Vogler BK , Pittler MH , Ernst E. The efficacy of ginseng. A systematic review of randomised clinical trials. Eur J Clin Pharmacol. 1999;55:567–75.PubMedCrossRef Vogler BK , Pittler MH , Ernst E. The efficacy of ginseng. A systematic review of randomised clinical trials. Eur J Clin Pharmacol. 1999;55:567–75.PubMedCrossRef
13.
go back to reference Oken BS , Storzbach DM , Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol. 1998;55:1409–15.PubMedCrossRef Oken BS , Storzbach DM , Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol. 1998;55:1409–15.PubMedCrossRef
14.
go back to reference Solomon PR , Adams F , Silver A , Zimmer J , DeVeaux R. Ginkgo for memory enhancement: a randomized controlled trial. JAMA. 2002;288:835–40.PubMedCrossRef Solomon PR , Adams F , Silver A , Zimmer J , DeVeaux R. Ginkgo for memory enhancement: a randomized controlled trial. JAMA. 2002;288:835–40.PubMedCrossRef
15.
go back to reference Pittler MH , Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. Am J Med. 2000;108:276–81.PubMedCrossRef Pittler MH , Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. Am J Med. 2000;108:276–81.PubMedCrossRef
16.
go back to reference Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2002(4):CD003120. Birks J, Grimley EV, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2002(4):CD003120.
17.
go back to reference Bent S , Goldberg H , Padula A , Avins AL. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature: a case report and systematic review of the literature. J Gen Intern Med. 2005;20:657–61.PubMedCrossRef Bent S , Goldberg H , Padula A , Avins AL. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature: a case report and systematic review of the literature. J Gen Intern Med. 2005;20:657–61.PubMedCrossRef
18.
go back to reference Stevinson C , Pittler MH , Ernst E. Garlic for treating hypercholesterolemia; a meta-analysis of randomized clinical trials. Ann Intern Med. 2000;133:420–9.PubMed Stevinson C , Pittler MH , Ernst E. Garlic for treating hypercholesterolemia; a meta-analysis of randomized clinical trials. Ann Intern Med. 2000;133:420–9.PubMed
19.
go back to reference Koren MJ. Statin use in a “real-world” clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial. Am J Med. 2005;118Suppl 12A16–21.PubMedCrossRef Koren MJ. Statin use in a “real-world” clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial. Am J Med. 2005;118Suppl 12A16–21.PubMedCrossRef
20.
go back to reference Burnham BE. Garlic as a possible risk for postoperative bleeding. Plast Reconstr Surg. 1995;95:213.PubMedCrossRef Burnham BE. Garlic as a possible risk for postoperative bleeding. Plast Reconstr Surg. 1995;95:213.PubMedCrossRef
21.
go back to reference Rose KD , Croissant PD , Parliament CF , Levin MB. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report. Neurosurgery. 1990;26:880–2.PubMedCrossRef Rose KD , Croissant PD , Parliament CF , Levin MB. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report. Neurosurgery. 1990;26:880–2.PubMedCrossRef
22.
go back to reference Linde K, Mulrow CD, Berner M, Egger M. St John’s wort for depression. Cochrane Database Syst Rev. 2005(2):CD000448. Linde K, Mulrow CD, Berner M, Egger M. St John’s wort for depression. Cochrane Database Syst Rev. 2005(2):CD000448.
23.
go back to reference Linde K , Ramirez G , Mulrow CD , Pauls A , Weidenhammer W , Melchart D. St John’s wort for depression—an overview and meta-analysis of randomised clinical trials. BMJ. 1996;313:253–8.PubMed Linde K , Ramirez G , Mulrow CD , Pauls A , Weidenhammer W , Melchart D. St John’s wort for depression—an overview and meta-analysis of randomised clinical trials. BMJ. 1996;313:253–8.PubMed
24.
go back to reference Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John’s wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002;287:1807–14.CrossRef Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John’s wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002;287:1807–14.CrossRef
25.
go back to reference Shelton RC , Keller MB , Gelenberg A , et al.. Effectiveness of St John’s wort in major depression: a randomized controlled trial. JAMA. 2001;285:1978–86.PubMedCrossRef Shelton RC , Keller MB , Gelenberg A , et al.. Effectiveness of St John’s wort in major depression: a randomized controlled trial. JAMA. 2001;285:1978–86.PubMedCrossRef
26.
go back to reference Hammerness P , Basch E , Ulbricht C , et al.. St John’s wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics. 2003;44:271–82.PubMedCrossRef Hammerness P , Basch E , Ulbricht C , et al.. St John’s wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics. 2003;44:271–82.PubMedCrossRef
27.
go back to reference Pittler MH , Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am J Gastroenterol. 1998;93:1131–5.PubMedCrossRef Pittler MH , Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am J Gastroenterol. 1998;93:1131–5.PubMedCrossRef
28.
go back to reference Ernst E , Pittler MH. Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials. Br J Anaesth. 2000;84:367–71.PubMed Ernst E , Pittler MH. Efficacy of ginger for nausea and vomiting: a systematic review of randomized clinical trials. Br J Anaesth. 2000;84:367–71.PubMed
29.
go back to reference Lethaby AE, Brown J, Marjoribanks J, Kronenberg F, Roberts H, Eden J. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev. 2007(4):CD001395. Lethaby AE, Brown J, Marjoribanks J, Kronenberg F, Roberts H, Eden J. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev. 2007(4):CD001395.
30.
go back to reference Taku K , Umegaki K , Sato Y , Taki Y , Endoh K , Watanabe S. Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr. 2007;85:1148–56.PubMed Taku K , Umegaki K , Sato Y , Taki Y , Endoh K , Watanabe S. Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr. 2007;85:1148–56.PubMed
31.
go back to reference Ulbricht C , Basch E. Natural standard herb and supplement reference: evidence-based clinical reviews. St. Louis, MO: Elsevier Mosby; 2005. Ulbricht C , Basch E. Natural standard herb and supplement reference: evidence-based clinical reviews. St. Louis, MO: Elsevier Mosby; 2005.
32.
go back to reference Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev. 2003(1):CD003383. Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev. 2003(1):CD003383.
33.
go back to reference Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products—United States, Germany, and Switzerland, 1999–2002. MMWR Morb Mortal Wkly Rep. 2002;51:1065–7. Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products—United States, Germany, and Switzerland, 1999–2002. MMWR Morb Mortal Wkly Rep. 2002;51:1065–7.
35.
36.
go back to reference Bent S , Ko R. Commonly used herbal medicines in the United States: a review. Am J Med. 2004;116:478–85.PubMedCrossRef Bent S , Ko R. Commonly used herbal medicines in the United States: a review. Am J Med. 2004;116:478–85.PubMedCrossRef
38.
go back to reference Nortier JL , Martinez MC , Schmeiser HH , et al.. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med. 2000;342:1686–92.PubMedCrossRef Nortier JL , Martinez MC , Schmeiser HH , et al.. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med. 2000;342:1686–92.PubMedCrossRef
39.
41.
42.
go back to reference Bent S , Tiedt TN , Odden MC , Shlipak MG. The relative safety of ephedra compared with other herbal products. Ann Intern Med. 2003;138:468–71.PubMed Bent S , Tiedt TN , Odden MC , Shlipak MG. The relative safety of ephedra compared with other herbal products. Ann Intern Med. 2003;138:468–71.PubMed
43.
go back to reference Shekelle PG , Hardy ML , Morton SC , et al.. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA. 2003;289:1537–45.PubMedCrossRef Shekelle PG , Hardy ML , Morton SC , et al.. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA. 2003;289:1537–45.PubMedCrossRef
44.
go back to reference DHHS, FDA. Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Final rule. Fed Regist. 2004;69:6787–6854. DHHS, FDA. Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Final rule. Fed Regist. 2004;69:6787–6854.
45.
go back to reference Hoffman BB , Taylor P. Neurotransmission. In: Hardman JG, Limbird LE, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 10New York, NY: McGraw-Hill; 2001:115–53. Hoffman BB , Taylor P. Neurotransmission. In: Hardman JG, Limbird LE, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 10New York, NY: McGraw-Hill; 2001:115–53.
46.
go back to reference Haller CA , Benowitz NL , Jacob P 3rd. Hemodynamic effects of ephedra-free weight-loss supplements in humans. Am J Med. 2005;118:998–1003.PubMedCrossRef Haller CA , Benowitz NL , Jacob P 3rd. Hemodynamic effects of ephedra-free weight-loss supplements in humans. Am J Med. 2005;118:998–1003.PubMedCrossRef
47.
go back to reference DHHS. Adverse event reporting for dietary supplements: An inadequate safety valve. US:: Office of the Inspector General, HHS.; 2001. DHHS. Adverse event reporting for dietary supplements: An inadequate safety valve. US:: Office of the Inspector General, HHS.; 2001.
48.
go back to reference Bent S , Padula A , Neuhaus J. Safety and efficacy of citrus aurantium for weight loss. Am J Cardiol. 2004;94:1359–61.PubMedCrossRef Bent S , Padula A , Neuhaus J. Safety and efficacy of citrus aurantium for weight loss. Am J Cardiol. 2004;94:1359–61.PubMedCrossRef
49.
go back to reference Colker C , Kalman D , Torina G , Perlis T , Street C. Effects of Citrus aurantium extract, caffeine, and St. John’s Wort on body fat loss, lipid levels, and mood states in overweight healthy adults. Curr Ther Res. 1999;60:145–53.CrossRef Colker C , Kalman D , Torina G , Perlis T , Street C. Effects of Citrus aurantium extract, caffeine, and St. John’s Wort on body fat loss, lipid levels, and mood states in overweight healthy adults. Curr Ther Res. 1999;60:145–53.CrossRef
52.
go back to reference Blendon RJ , DesRoches CM , Benson JM , Brodie M , Altman DE. Americans’ views on the use and regulation of dietary supplements. Arch Intern Med. 2001;161:805–10.PubMedCrossRef Blendon RJ , DesRoches CM , Benson JM , Brodie M , Altman DE. Americans’ views on the use and regulation of dietary supplements. Arch Intern Med. 2001;161:805–10.PubMedCrossRef
53.
go back to reference Eisenberg DM , Davis RB , Ettner SL , et al.. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA. 1998;280:1569–75.PubMedCrossRef Eisenberg DM , Davis RB , Ettner SL , et al.. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA. 1998;280:1569–75.PubMedCrossRef
54.
go back to reference Lewis JD , Strom BL. Balancing safety of dietary supplements with the free market. Ann Intern Med. 2002;136:616–8.PubMed Lewis JD , Strom BL. Balancing safety of dietary supplements with the free market. Ann Intern Med. 2002;136:616–8.PubMed
55.
go back to reference Marcus DM , Grollman AP. Botanical medicines—the need for new regulations. N Engl J Med. 2002;347:2073–6.PubMedCrossRef Marcus DM , Grollman AP. Botanical medicines—the need for new regulations. N Engl J Med. 2002;347:2073–6.PubMedCrossRef
56.
go back to reference Jacobs BP , Bent S , Tice JA , Blackwell T , Cummings SR. An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. Medicine (Baltimore). 2005;84:197–207.CrossRef Jacobs BP , Bent S , Tice JA , Blackwell T , Cummings SR. An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. Medicine (Baltimore). 2005;84:197–207.CrossRef
57.
go back to reference Fugh-Berman A. The 5-Minute Herb & Dietary Supplement Consult. Philadelphia, PA: Lippincott Williams & Wilkins; 2003. Fugh-Berman A. The 5-Minute Herb & Dietary Supplement Consult. Philadelphia, PA: Lippincott Williams & Wilkins; 2003.
Metadata
Title
Herbal Medicine in the United States: Review of Efficacy, Safety, and Regulation
Grand Rounds at University of California, San Francisco Medical Center
Author
Stephen Bent
Publication date
01-06-2008
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 6/2008
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-008-0632-y

Other articles of this Issue 6/2008

Journal of General Internal Medicine 6/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.